Next Article in Journal
Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors
Previous Article in Journal
Molecular Regulation of Copper Homeostasis in the Male Gonad during the Process of Spermatogenesis
Open AccessReview

Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis

1
Center of Tobacco Control Research, DK-5230 Odense M, Denmark
2
Department of Oncology, Western University, London, ON N6A 5W9, Canada
3
Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
4
Department of Nuclear Medicine, University of Muenster, Albert-Schweitzer-Campus 1, 48149 Muenster, Germany
5
Department of Nuclear Medicine, University of Ankara, 06800 Ankara, Turkey
6
Division of Nuclear Medicine, University Hospital, 1010 Vienna, Austria
7
Department of Nuclear Medicine, University Hospital Innsbruck, 6020 Innsbruck, Austria
8
Department of Molecular Radiotherapy and Molecular Imaging, Zentralklinik, 99438 Bad Berka, Germany
9
Theranostics Center, Johan Wolfgang Goethe University Frankfurt/Main, 60437 Frankfurt, Germany
10
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori (IRST) IRCCS, 7014 Meldola, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(23), 9054; https://doi.org/10.3390/ijms21239054
Received: 21 October 2020 / Revised: 17 November 2020 / Accepted: 24 November 2020 / Published: 28 November 2020
(This article belongs to the Special Issue PSMA in Prostate Cancer)
The aim of the review was to evaluate patient and treatment characteristics for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with PSMA radioligand therapy (PRLT) associated with above-average outcome. The systematic review and meta-analysis followed recommendations by the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA). We searched for publications in PubMed, Embase, and ClinicalTrials.gov up to 31 September 2020. Thirty-six publications and four duplicates reported 2346 patients. Nearly two-thirds of the patients had bone metastases. Median overall survival (OS) was 16 months. Asymptomatic patients and patients with only lymph node metastases lived longer than symptomatic patients and patients with more extensive metastases. Patients treated with an intensified schedule of 177Lu PRLT lived longer than those treated with a conventional schedule. Half of the patients obtained a PSA decline ≥ 50% and these patients lived longer than those with less PSA decline. Approximately 10% of the patients developed hematologic toxicity with anemia grade 3 as the most severe adverse effect. Characteristics for patients, cancer, restaging, and PRLT predict above average overall survival following treatment with PRLT. View Full-Text
Keywords: adverse effects; decline of prostate specific antigen; metastases; overall survival; predictive factors; prostate cancer; prostate-specific membrane antigen; theranostics adverse effects; decline of prostate specific antigen; metastases; overall survival; predictive factors; prostate cancer; prostate-specific membrane antigen; theranostics
Show Figures

Figure 1

MDPI and ACS Style

von Eyben, F.E.; Bauman, G.; von Eyben, R.; Rahbar, K.; Soydal, C.; Haug, A.R.; Virgolini, I.; Kulkarni, H.; Baum, R.; Paganelli, G. Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis. Int. J. Mol. Sci. 2020, 21, 9054. https://doi.org/10.3390/ijms21239054

AMA Style

von Eyben FE, Bauman G, von Eyben R, Rahbar K, Soydal C, Haug AR, Virgolini I, Kulkarni H, Baum R, Paganelli G. Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 2020; 21(23):9054. https://doi.org/10.3390/ijms21239054

Chicago/Turabian Style

von Eyben, Finn E.; Bauman, Glenn; von Eyben, Rie; Rahbar, Kambiz; Soydal, Cigdem; Haug, Alexander R.; Virgolini, Irene; Kulkarni, Harshad; Baum, Richard; Paganelli, Giovanni. 2020. "Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis" Int. J. Mol. Sci. 21, no. 23: 9054. https://doi.org/10.3390/ijms21239054

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop